Connect with us

CANNABIS

Israel Isolates a Canadian Greenhouse in Its Dumping Probe

Israel’s new cannabis dumping sample pulls greenhouse GrowCo out of the indoor pack, covering most Canada-Israel flower after a 165 percent duty already died.

Published

on

Israel’s trade-levies commissioner named four Canadian cannabis exporters on October 22, 2026, for an in-depth anti-dumping review that isolates a greenhouse responsible for most of the flow. Danny Tal, who runs the unit at the Ministry of Economy and Industry, put Cronos GrowCo in its own column and grouped three so-called premium growers as a sample of the rest. He has not published a preliminary duty.

The four names are the headline. The split is the file. Tal is measuring a greenhouse that already feeds Israel’s top medical brand against indoor and hybrid rooms he describes as higher cost, after a 165 percent levy on this trade died in 2025 on patient-price and budget grounds.

The Sample Puts a Greenhouse in Its Own Column

Twenty-two Canadian firms filed opening answers and questionnaires. Seventeen had shipped medical cannabis to Israel in the period under review. Tal wrote that working out a dumping margin for every exporter in time was not practical, so the ministry will not try.

World Trade Organization anti-dumping rules start from an individual margin for each known exporter. When the crowd is too large, authorities may limit the work to statistically valid samples of exporters or to the largest share of export volume they can reasonably study, preferably after talking with the firms. Israel is using both doors at once, and it has added a growing-method cut on top.

HOW THE FOUR WERE PICKED

  • The indoor pack: Cielo Verde Quebec Inc., 2323414 Alberta Ltd. and Koots Canna Ltd. stand in as a sample of 16 premium indoor and hybrid growers that sent data, and those three account for about 22 percent of that group’s exports.
  • The greenhouse: GrowCo is reviewed on its own because of its volume and because it grows under glass, which the commissioner sets against higher-cost indoor operators.
  • The coverage claim: Together the four names account for about 70 percent of all Canadian cannabis exports to Israel, per the October 22 notice.
  • The objection clock: Parties have five business days from October 22, 2026, to file written comments or objections on the sample method before Tal locks it in.

The notice, described to the parties, says GrowCo supplied more than 60 percent of Canadian cannabis exports to Israel in the investigation period and ships that flower to Cronos Israel. Volume alone would have put the greenhouse in the file. The extra move is the cost contrast with indoor rooms, because a dumping margin is a gap between an export price and a “normal” value, often built from home-market prices or from costs plus profit. Cheaper greenhouse costs can look like dumping if the comparison set is indoor.

GrowCo, Cielo Verde and the Alberta Number

GrowCo is Cronos Growing Company Inc., a purpose-built cultivation joint venture. Cronos Group holds a 50 percent equity stake with greenhouse partners and, from July 1, 2024, consolidated the results after it took majority control of the board. The company’s annual filing says the site is licensed to export dried flower to Israel and holds Global GAP and ICANN GAP certifications aimed at that lane.

Peace Naturals Project Inc., Cronos’s wholly owned licence holder near Stayner, Ontario, is a separate campus. The brand on Israeli pharmacy shelves is Peace Naturals. The greenhouse under review is GrowCo. Cronos Israel, which holds the local GAP, GMP and GDP papers, is the buyer on that side of the water.

In the second quarter of 2026 Cronos posted US$53 million of net revenue, up 58 percent from a year earlier. Israel delivered its tenth straight quarter of record net revenue, up 60 percent as reported and 32 percent in constant currency, and Peace Naturals remained the country’s leading cannabis brand on the pharmacy data Cronos collects. Chief executive Mike Gorenstein told investors on the August 6, 2026, call that a new dumping probe had opened the day before, after an earlier case that never produced a duty. Emily Whalen, then Cronos’s senior manager of corporate communications, had already put the company’s line on the record in June.

Our position has not changed, Cronos does not engage in dumping.

Emily Whalen, Senior Manager, Corporate Communications, Cronos Group

Whalen said Cronos Israel obtained commercial medical licences in 2017, employs about 80 people, and has put more than 100 million shekels into a greenhouse, a manufacturing site and a cannabinoid testing lab in Israel. A punitive tariff, she said, would take a major supplier of medicine off the market, raise costs, and cut the product mix patients use. Koots Canna declined to comment on the October 22 sample. Cronos, CannaPharmaRx and Cielo Verde were not immediately available that week.

THE FOUR EXPORTERS IN THE SAMPLE

Company Home base Sample role Israel channel
GrowCo (Cronos Growing Company) Ontario greenhouse Individual review Cronos Israel / Peace Naturals
Cielo Verde Quebec Inc. Quebec Premium indoor/hybrid sample Previously Green Boys and Sheach
2323414 Alberta Ltd. Cremona, Alberta, via CannaPharmaRx Inc. Premium indoor/hybrid sample Cannapharma, marketed by Formosa (formerly Cantec)
Koots Canna Ltd. British Columbia Premium indoor/hybrid sample Canndoc

CannaPharmaRx, parent of the Alberta numbered company, has described an indoor room setup in Cremona and IMC-GAP papers for Israel. That fits the commissioner’s indoor and hybrid bucket even if the firm is small next to GrowCo. Public detail on Cielo Verde and Koots Canna is thinner; they matter here because Tal seated them as the stand-in for everyone else who grows under lights.

What a 125 Percent Margin Was Built On

The August 2026 restart, notified to the Embassy of Canada on August 2 and opened publicly on August 5, set a dumping window of July 2025 to June 2026 and an injury window of July 2023 to June 2026. In that trade window Canada shipped cannabis to Israel worth C$107,954,748. All other countries combined shipped C$37,045,648, so Canadian flower was about three-quarters of the import value on the file.

Tal’s opening math, attached to that restart, said Canadian medical cannabis was arriving at dumping prices. He put a prima facie margin of approximately 125 percent between an export price to Israel of about 4.43 shekels per gram (about C$2.07) and a claimed Canadian home price of about 10 shekels per gram. That gap is the complaint’s starting gun, not a duty. The sample is how he plans to test or replace it with company-level numbers.

THE PRICE GAP IN THE NEW COMPLAINT

  • Export price: About 4.43 shekels per gram to Israel, or about C$2.07 a gram, in the commissioner’s opening paper.
  • Home price used: About 10 shekels per gram in Canada, the figure the complaint treats as normal value.
  • Opening margin: Approximately 125 percent, which is the gap divided by the export price, before any company-specific adjustments.
  • What it is not: A published duty; Tal has not issued a preliminary dumping decision on this restart.

The complainants on the May 28, 2026, filing were Trichome Ltd. and Evergreen Solomon Pharma Ltd., Israeli growers arguing that local output was shrinking, shelf prices were rising, and the domestic industry was sliding. They pointed to “constructive importers” that bring in flower without running local grow sites, and to small mixed lots, including packs around 20 kg, that local farms say they cannot match on variety. About 15 domestic growers were listed as supporting the complaint. The August notice named a long importer roster that already included Cronos Israel, Canndoc, Seach Medical and Cantek Global, the same channels now sitting behind the sampled names.

Smotrich Vetoed 165 Percent Duties in 2025

This is the third run at the same fight. The first probe opened in January 2024. A July 2024 preliminary paper floated company rates from 63 percent to 369 percent. A November 2024 final report talked in terms as high as 175 percent. On April 10, 2025, Economy and Industry Minister Nir Barkat adopted a 165 percent levy for four years on Canadian cannabis, with lower company rates for Decibel at 12 percent, Village Farms at 28 percent, Organigram at 53 percent and Tilray at 70 percent, firms that local coverage said were no longer shipping much into Israel.

Finance Minister Bezalel Smotrich blocked it. In an eight-page letter he told Barkat the levy would freeze the market’s growth, both at home and abroad, and would hurt the mix of capital in the Israeli economy. He also flagged patient access. The Prime Minister’s legal adviser, in a 15-page opinion circulated on July 3, 2025, and signed for the economic-law department by Dr. Yuval Roitman, found no legal basis to cancel the veto. Health officials and the competition authority had already objected to the method and to the price effect.

A significant impact on imports as a result of the imposition of the levy would prevent the market’s growth potential, both domestically and globally, and would harm the diversification of the sources of capital and growth of the Israeli economy.

Bezalel Smotrich, Minister of Finance, letter to the Minister of Economy and Industry, April 2025

The veto file listed three practical reasons. The medical cannabis market was generating over a billion shekels a year. A levy was expected to add tens of millions of shekels a year to the state’s bill for cannabis supplied to about 15,000 disabled IDF soldiers and victims of hostilities. And the tax cut against a stated policy of opening imports to hold down living costs. Global Affairs Canada, in its 2025 response to the first findings, said it had significant concerns with the commissioner’s methodological choices and would keep watching the case.

THE PATH TO THIS SAMPLE

  1. January 2024: Opens the first anti-dumping probe into Canadian medical cannabis.
  2. April 10, 2025: Economy minister adopts a 165 percent levy for four years, with four company exceptions.
  3. April 2025: Finance minister vetoes the levy on growth, patient-cost and competition grounds.
  4. July 3, 2025: Prime Minister’s legal adviser upholds the veto in a 15-page opinion.
  5. June 29, 2026: Opens a new probe on a complaint from Trichome Ltd. and Evergreen Solomon Pharma Ltd.
  6. July 28, 2026: Closes that probe because Canada was not notified before launch, a step required under WTO anti-dumping rules.
  7. August 2, 2026: Notifies the Embassy of Canada, then reopens the case in public on August 5.
  8. October 22, 2026: Names GrowCo plus three premium growers as the in-depth sample.

Jerusalem District Court had already rejected a grower petition against the block in December 2025. The June 2026 reboot then died on a human error: notice never went to Global Affairs Canada before the case went public. The August papers fixed that sequencing. A June notice on the ministry’s own file had also told parties a preliminary finding within 60 to 90 days was the statutory clock. The August restart sits on a similar timetable. Sample selection arrived instead of a duty.

Who Sells This Flower Inside Israel

The Canadian names on Tal’s list are not the shops. Canndoc, the InterCure production arm, markets Koots Canna’s products. Formosa, formerly Cantec, markets the Alberta company’s Cannapharma line. Cielo Verde’s flower was previously sold by Green Boys and Sheach. GrowCo’s output moves through Cronos Israel under Peace Naturals. If duties land, those importers and the pharmacies behind them are the first price-setters patients see.

That is why the 2025 veto spent so many pages on the state’s own cannabis bill. About 15,000 people on IDF disability and hostility-victim programmes receive government-funded flower. A levy that lifts import prices does not stop at a grower’s loading dock; it shows up in a reimbursement line. Yuval Landschaft, who headed the Health Ministry’s medical cannabis unit during the first case, would not support Tal’s conclusions, citing gaps in the facts and the method. The competition authority also rejected the proposed tariffs.

Barkat did not let the argument rest. At a Knesset Finance Committee session on January 19, 2026, he said that after the treasury blocked the levy, consumer prices rose 10 percent in 2025, Israeli farms went under, and import dependence grew. Committee chair Hanoch Milwidsky, speaking for the committee, asked the finance minister to revisit levies on both Chinese aluminium and Canadian cannabis. The new sample is how that political argument has been rebuilt as a trade file, with greenhouse costs written into the method rather than left for a later ministerial fight.

Israel Took About 8 Percent of Canada’s Exports

Israel, a country of about 10 million people, is a regular top-ten destination for Canadian medical cannabis, with Germany, Portugal, Australia and the United Kingdom. It is not the engine of the Canadian export book. Health Canada publishes the underlying cannabis import and export data as permitted and endorsed quantities under the Cannabis Act, which only allows medical or scientific shipments plus industrial hemp.

In the first seven months of 2026, Canadian companies shipped more than 18,000 kg of cannabis to Israel, worth C$29.6 million. That was about 8 percent of Canada’s total cannabis exports of 236,822 kg in the same stretch. Germany took more than 92,000 kg. A duty that reroutes or reprices the Israel lane would sting the four sampled exporters, and it would sting Cronos Israel in a quarter where that unit is still setting revenue records. It would not, on these tonnes, rewrite Canada’s German book.

WHERE THE TONNES WENT, JANUARY TO JULY 2026

Destination Volume Value / share
Germany More than 92,000 kg Largest country volume in the period
Israel More than 18,000 kg C$29.6 million; about 8 percent of Canada’s 236,822 kg
All destinations 236,822 kg Canadian total for the seven months

Organigram Global, a Canadian exporter that is not in this four-name sample, said in October 2026 that Canada’s medical cannabis export volumes passed 275 tonnes in 2025, more than double the year before, with none of that book hanging on the United States. That national scale is the backdrop for Tal’s case. Israeli indoor farms are arguing over a lane that is large in Tel Aviv pharmacies and modest in the Canadian total, except at GrowCo, where the same lane is the feed for a brand on a ten-quarter run.

No Preliminary Duty Has Been Published

Tal has told the parties he will read the sample objections and then freeze the list. After that comes the company-level cost work: GrowCo’s greenhouse accounts on one sheet, the three premium rooms on another, and a residual rate for everyone else who shipped in the period and is not individually reviewed. Voluntary extra filings are supposed to be taken if they arrive in time, which is the WTO’s safety valve when a sample is used.

Israeli trade-levy law also lets the commissioner issue a preliminary decision, and a bond or guarantee can follow, on a 60-to-90-day clock from opening. He used a provisional duty of 61 percent to 146 percent on Chinese aluminium profiles in May 2025 while that case was still live. The cannabis restart is inside a similar window, and still has no published prelim. The last time a full 165 percent landed on his desk, the finance minister killed it, and the legal adviser backed the kill, because of patients, a billion-shekel market, and a state bill for about 15,000 funded users.

The sample now on the table is built so the next number, if one comes, will be a greenhouse margin set next to an indoor sample, covering about 70 percent of the Canada-Israel flow before anyone else is even priced. Cronos says it does not dump. Koots Canna had no comment. The pharmacies that already sell this flower, and the patients whose scripts sit on those shelves, are not named in the caption of the October 22 notice, and they are the ones who paid the last time this levy was priced.

Disclaimer: This article is news reporting and analysis of a live Israeli trade-remedy process and is for information only. It is not legal advice on anti-dumping procedure, not investment advice on any listed cannabis company, and not medical advice about cannabis products or patient access. Readers who may be affected as exporters, importers, patients or investors should consult a qualified trade lawyer, a licensed medical clinician, or a registered financial adviser before acting. Company names, volumes, prices and case status are taken from ministry notices, company filings and public datasets as of the dates given in the piece and can change as the sample is finalized or as a preliminary duty is issued or withheld.

Harry is the editor and lead writer of MMJ GAZETTE, an independent title on medical cannabis that he owns and runs, covering the science, patient programs, products and the laws that decide who can use them. Ten years of journalism sit behind the site, the first of them as a reporter and the later ones as an editor, with medical cannabis taking up most of that decade. His reporting is built on the clinical literature and the rulebooks: peer-reviewed trials and systematic reviews, trial registry entries, dosing and safety data, the enabling statutes and program rules for each medical scheme, and the guidance issued to prescribers. Study results are reported with their sample size, comparator and confidence interval, each checked against the paper itself before publication, and a claim that outruns the evidence is cut. When an error is found, the article is corrected and a dated note records the change, in line with the site's public corrections policy. Medical cannabis remains illegal in many places and the articles are not treatment advice, so patients should talk with a clinician who knows their history. Reader questions go to support@mmjgazette.com.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending